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ALLERGY—Cost Studies
PAA1
LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS 
CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS
Bachert C1, Demarteau N2
1Ghent University Hospital, Belgium; 2UCB pharma, Braine-l’Alleud,
Belgium
Persistent allergic rhinitis (PER) is a frequent disease often asso-
ciated with co-morbidities (asthma, sinusitis, otitis media and
upper respiratory infection) and a signiﬁcant economic burden.
Levocetirizine is an antihistamine, the ﬁrst-line treatment of
allergic rhinitis. OBJECTIVES: To determine the monetary
impact of a long-term levocetirizine treatment either from a soci-
etal perspective or from an employer perspective. METHODS:
XPERT trial was a 6-month double-blind placebo-controlled
trial comparing levocetirizine 5mg once daily to placebo. A total
of 551 patients were included (69% working). Parameters mea-
sured, all related to PER or its co-morbidities, were health care
resources (medications, physician visits and hospitalizations) col-
lected in the case report form as well as workdays and usual daily
activities (UDA) lost collected through a speciﬁc questionnaire.
French monetary values from 2000 were applied and compared
using a bootstrap-t analysis. The societal perspective included all
costs for all patients while the employer perspective included the
cost of workdays lost for working patients. RESULTS: The
overall cost from the societal perspective was of 412.93€ per
patient per month in the placebo vs. 232.23€ in the levocetirizine
group. This led to a gain of 180.70€ per patient per month in
the levocetirizine group (p-value <0.001). UDA lost was the cost
driver (≥ 66%). The overall costs from an employer perspective
was of 152.24€ per working patient per month in the placebo
vs. 89.61€ in the levocetirizine group leading to a gain of 62.63€
per working patient per month (p-value <0.001). CONCLU-
SION: Levocetirizine reduces the overall cost associated with
PER and its co-morbidities both for employers and society. These
savings are due to a reduction in the cost of work and UDA days
lost that more than offset the cost of the levocetirizine treatment.
PAA2
PUBLIC HEATH SYSTEM EXPENSES ON CHILDREN’S ATOPIC
DERMATITIS TREATMENT IN VLADIVOSTOK CITY
Derkach V, Prosekova E
Far East Branch of Scientiﬁc Research Institute of Clinic Immunology,
Vladivostok, Russia
OBJECTIVES: Pharmacological and economic analysis of public
health system expenses on children’s atopic dermatitis.
METHODS: Evaluation of cost and expenses on the disease
included expenditures on hospital and ambulatory assistance and
sanatorium-and-spa treatment. In 2000–2003, children’s medical
institutions of Vladivostok city held a survey of 200 families with
children suffering from atopic dermatitis and analysis of medical
documentation. RESULTS: Volume of expenses was determined
to a great extent by severity of the disease clinical course and
spread of atopic dermatitis. Number of recourses to medical
assistance with light course of the disease was in most cases not
more that four times per year and was restricted to outpatient
treatment only, the cost of treatment amounted to 600–1400
rubles ($20–47) per child per year. In case of severe course and
poor control over the disease number of recourses increased up
to 14–20 per year, the expenses included cost of consultations of
allergologist and dermatologist and amounted up to 2100–7000
rubles ($322–406) per year. Further worsening of case required
hospital treatment expenses. On average, 0.37 cases of hospital
treatment fall at one child with atopic dermatitis per year, with
severe clinical course this value increased up to 1.34 ± 0.2 cases,
treatment duration was 15.62 ± 1.02 days. Average cost of hos-
pital treatment per a child suffering from atopic dermatitis 
in 2000–2003 was 2775.84–3675.69 rubles ($86–124),
1922.7–2896.1 rubles ($60–98) and 3793.1–5713.5 rubles
($118–193) in allergologic, dermatologic and pediatric divisions
respectively. Expenses on 21 days of sanatorium-and-spa treat-
ment in Primorsky region amounted to 12,000 rubles ($406) and
were registered in 2.4% of families with children suffering from
atopic dermatitis. CONCLUSIONS: Atopic dermatitis requires
considerable expenses on medical treatment from public health
system as well as expenses on pharmacotherapy from patient.
ASTHMA
ASTHMA—Cost Studies
PAA3
RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF
ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF
SEVERITY IN FIVE EUROPEAN COUNTRIES
Piercy J1, Benford M2, Milligan G2, Karavali M2
1Adelphi Group, Bollington, Cheshire, UK; 2Adelphi Group Products,
Bollington, Cheshire, UK
OBJECTIVE: Patients with asthma consume signiﬁcant amounts
of health care resources. The purpose of this study was to inves-
tigate differences in resource use for patients with different
degrees of severity of asthma. METHODS: The data are drawn
from the Adelphi Disease Speciﬁc Programme (DSP) in Asthma,
undertaken in 2003. DSPs are cross-sectional studies of consult-
ing patients. One of the aims of the DSP was to collect infor-
mation about the treatment of asthma from the perspective of
both the doctor and the patient. Data were collected by a panel
of doctors who were asked to include the ﬁrst 10 patients con-
sulting for asthma from a speciﬁed start date. The study included
2610 patients with asthma of greater than 12 months duration
in France, UK, Germany, Italy and Spain. RESULTS: Patients
were segmented by their doctor into one of four categories: inter-
mittent (28%), mild persistent (15%), moderate persistent
(49%) and severe persistent (8%). Patients with intermittent
asthma had a mean of 0.37 emergency room visits, 0.06 hospi-
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talisations and 2.3 physician visits speciﬁcally for the treatment
of asthma exacerbations in the last 12 months. Patients in other
groups consumed more resources. Patients with mild persistent
asthma had 0.57 emergency room visits, 0.09 hospitalisations
and 3.1 physician visits. The means for moderate patients were
0.61, 0.25 and 3.66 respectively, and for severe patients 1.22,
1.98 and 6.22. Patients in Germany and France were most likely
to seek primary care treatment; though patients in Italy and the
UK were most likely to be hospitalised. CONCLUSION: The
data show that the likelihood of resource use of patients with
exacerbations of asthma increases with the underlying level of
severity. From these data, it is clear that better control and man-
agement of asthma exacerbations can result in resource use
savings.
PAA4
A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND
COST-EFFECTIVENESS OF SALMETEROL AND
MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M1, Plisko R1, Landa K1, Glogowski C2, Gierczynski J2
1HTA Consulting, Krakow, Poland; 2GlaxoSmithKline Pharmaceuticals
S.A, Warszawa, Poland
OBJECTIVES: To compare efﬁcacy and safety of salmeterol and
montelucast in adults with chronic bronchial asthma and cost-
effectiveness from payer’s and social perspective. METHODS:
The analysis was based on a systematic review. The efﬁcacy and
safety of salmeterol and montelucast were compared. Costs were
estimated on the basis of current cost of medication and pro-
ductivity loss in Poland. The time horizon of 12 weeks was
taken. The ratio of cost difference and efﬁcacy difference
(episode-free days—EFD) was calculated in incremental analy-
sis. RESULTS: The efﬁcacy analysis showed that statistically sig-
niﬁcant higher EFD ratio is achieved with salmeterol (32%) than
with montelucast (26%). Direct and indirect cost analyses of the
two options show that lower costs are generated by the use of
salmeterol. The use of montelucast in place of salmeterol results
in smaller health beneﬁt, and concomitantly, higher treatment
costs. The use of salmeterol in place of montelucast in a period
of 12 weeks in one patient is associated with gain of additional
5 days free of asthma symptoms. The estimated difference in a
period of 12 weeks of administration is approximately PLN 157
(34€) and PLN 248 (54€) per patient from payer’s and social per-
spective, respectively favouring salmeterol. The multivariate sen-
sitivity analysis was performed and conﬁrmed the robustness of
results. CONCLUSIONS: Salmeterol is a dominant option in
relation to montelucast in the treatment of bronchial asthma.
Salmeterol should be used before administration of montelucast.
Both perspectives concluded that administration of salmeterol
will result in payers budget savings—PLN680 (149€) per one
patient year. Conducting of prospective studies of indirect cost
of asthma treatment is recommended.
PAA5
A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND
COST-EFFECTIVENESS OF FLUTICASONE AND
MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M1, Plisko R1, Landa K1, Glogowski C2, Gierczynski J2
1HTA Consulting, Krakow, Poland; 2GlaxoSmithKline Pharmaceuticals
S.A, Warszawa, Poland
OBJECTIVES: Assessment of efﬁcacy and safety of ﬂuticasone
and montelucast in treatment of adult patients with chronic
bronchial asthma and cost-effectiveness from payer’s and social
perspective. METHODS: Comparison of efﬁcacy and safety
were based on valid RCTs found in systematic reviews. Costs
were estimated on the basis of current cost of medications and
productivity loss in Poland. In the incremental analysis, the ratio
of social cost difference and efﬁcacy difference was calculated.
Multivariate sensitivity analysis was performed. RESULTS: Sta-
tistically signiﬁcantly higher efﬁcacy of ﬂuticasone over mon-
telucast has been demonstrated in relation to the following end
points: asthma symptom score, episode-free days, and supple-
mental rescue medications. There is no signiﬁcant difference
among treatment groups with respect to exacerbations and other
adverse events. Both options are safe and no difference in safety
has been demonstrated. The use of montelucast instead of ﬂuti-
casone results in smaller health beneﬁt for the patients, and con-
comitantly, higher treatment costs. The estimated difference in a
period of 24 weeks of administration is approximately PLN 733
(163€) and PLN 1401 (306€) per patient from payer’s and social
perspective, respectively favouring ﬂuticasone. The use of ﬂuti-
casone in place of montelucast for a period of 24 weeks in one
patient is associated with gained additional 14.6 days free of
asthma symptomps. Multivariate sensitivity analysis conﬁrmed
robustness of the results. CONCLUSIONS: Based on the con-
ducted cost-effectiveness analysis, it may be concluded that ﬂu-
ticasone is a dominant option over montelucast in the treatment
of bronchial asthma. Both perspectives concluded that adminis-
tration of ﬂuticasone will result in payers budget savings—
PLN1596 (348€) per one patient year. Prospective studies on
indirect costs of asthma treatment methods should be conducted.
ASTHMA
ASTHMA—Health Policy
PAA6
IMPACT OF A DISEASE MANAGEMENT PROGRAM ON
CONTROL OF ASTHMA IN NORMANDY
Launois R1, Salmeron S2, Lançon F3, Perez V4, Gailhardou M3,
Roy M4, Magar Y5, Queniart-Stojanovic M3, Godard P6
1REES France, Paris, France; 2Hopital Saint Joseph, Paris, France;
3Fedialis Medica Groupe GSK, Marly Le Roi, France; 4Caisse Primaire
D’Assurance Maladie D’Evreux, Evreux, France; 5EduSanté,Vanves,
France; 6Centre Hospitalier Universitaire (C.H.U), Montpellier, France
OBJECTIVES: Assess whether a disease management program
of asthma (DMPA) improves quality of care and reduces costs
compared to standard care (SC). METHODS: A prospective
“Before/After” quasi-experimental design was chosen. SC was
observed during the ﬁrst 18 months. DMPA involved training
doctors in existing guidelines in asthma, implementing asthma
education sessions and investments in computerised GP’s data
collection (with asthma template) Impact of DMPA was studied
in the subsequent 18 months. Control rate of asthma (CRA) was
deﬁned according to the Canadian asthma consensus criteria,
quality of life (QOL) measured by the Juniper scale and direct
and productivity costs assessed from the perspective of society.
The expenditure discount rate was three percent (3%). Three
regions were followed in parallel, to conﬁrm trends observed on
the experimental site were due to the DMPA. RESULTS: A total
of 32 volunteer general practitioners and 313 asthmatic patients
were recruited on the experimental site, of which 145 patients
took part in both phases of the study. There was an absolute
improvement on the average quarterly CRA of 11% (p < 0.003):
65% (±3%) in the DMPA group vs. 54% (±3%) for the SC
group; a relative gain of 20%. Differences in the patient’s QOL
were signiﬁcant in favour of DMPA (p < 0.05) for three domains
and on the overall score. Absolute reduction in the average quar-
terly costs reached 24% (p < 0.003): 247€ in the DMPA group
compared to 187.4€ for the SC group. Asthma drug costs were
not signiﬁcantly modiﬁed (p = 0.129). Meanwhile, in the paral-
